Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288160 | 0.80 | ROCK1 (0.41) | CYP17A1 | |
| SCHEMBL288876 | 0.78 | ROCK1 (0.39) | CYP17A1 | |
| SCHEMBL6762394 | 0.67 | ROCK1 (0.51) | CYP17A1 | |
| SCHEMBL4496039 | 0.65 | HTT (0.35) | — | |
| SCHEMBL12715052 | 0.64 | MAP3K14 (0.56) | CYP17A1 | |
| SCHEMBL3238889 | 0.63 | ROCK1 (0.40) | CYP17A1 | |
| SCHEMBL288791 | 0.62 | ROCK1 (0.61) | — | |
| SCHEMBL3231004 | 0.62 | ROCK1 (0.38) | CYP17A1 | |
| SCHEMBL1774811 | 0.62 | CYP1A2 (0.57) | — | |
| SCHEMBL31205913 | 0.61 | CNR2 (0.43) | CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | CYP17A1 1390/4885GRM5 46/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | CYP17A1 1221/4885GRM5 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.